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Background
Africa presents with the world’s highest malaria incidence: 
85% of cases and 90% of malaria-related deaths.1 The continent 
is home to the most efficient vector mosquitoes in the world, 
the climate of much of sub-Saharan Africa is suitable for 
transmission, socio-economic factors constrain spending 
on national treatment and control measures, much of the 
population is poor and rural with little access to curative 
or public health measures, and resistance to antimalarial 
drugs and insecticides is rife.2 In many African countries, the 
ready availability of antimalarials without prescription, and 
incompleted treatment courses, contribute to drug pressure, 
and the range of antimalarial drug options is limited. HIV has 
worsened the effects of malaria in many respects, depending 
on the degree of acquired immunity.
Malaria in South Africa
Africa has a spectrum of malaria epidemiology ranging from 
intense year-round transmission to unstable, epidemic-prone 
areas. South Africa is fortunate in several ways regarding 
malaria: it is at the southern extreme of malaria distribution in 
Africa; relatively small areas experience seasonal transmission 
(hence malaria is unstable and epidemic-prone);3 a well-
organised national malaria control programme exists; and the 
country has a relatively well-developed scientific, economic 
and health infrastructure.
History of malaria control in South Africa
Malaria was recognised as a major cause of illness and death 
by early settlers and travellers in southern Africa. In the mid-
19th century, the early pioneers leaving the non-malarious 
Cape Province soon experienced the menace of malaria in the 
northern Transvaal. Gear4 wrote:
‘In South Africa, prior to the implementation of malaria 
control, transmission extended as far south as Durban and 
even Port St Johns, and inland as far as Pretoria during 
favourable years, causing large epidemics with up to 20 000 
deaths. During the 1930s the indoor feeding habits of malaria 
vectors were recognized and indoor space spraying with 
pyrethrum on a weekly basis was introduced. Together 
with oiling of suitable larval habitats a considerable degree 
of control was achieved. The breakthrough came with the 
availability and use of DDT and other long-lasting insecticides 
from 1945 which replaced the pyrethrum spraying and resulted 
in a dramatic interruption of malaria transmission in virtually 
all areas, with the disease becoming restricted to parts of the 
north-eastern low-lying areas, and the vector Anopheles funestus 
being eradicated. Active surveillance of malaria infections 
and treatment was intensified in the 1960s, further decreasing 
malaria transmission. Drs Annecke, Park-Ross and Botha de 
Meillon were among those responsible for these achievements.’ 
Epidemiology of malaria in South Africa
Malaria is endemic in the low-altitude areas of the northern 
and eastern parts of South Africa along the border with 
Mozambique and Zimbabwe, with transmission taking 
place mainly in Limpopo, Mpumalanga and KwaZulu-Natal 
provinces, and occasionally in North West province. The 
population at risk for contracting malaria in South Africa 
is approximately 4.3 million. The major strategies for the 
Malaria Control Programme in South Africa are vector control 
through indoor residual spraying, case management, disease 
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Control measures have substantially reduced the historical 
distribution of malaria in South Africa; the country’s 
population currently at risk for contracting malaria is 
approximately 4.3 million, predominantly in the northern 
and eastern border areas. The major strategies for malaria 
control are vector control through indoor residual 
spraying, case management, disease surveillance, epidemic 
preparedness and response, and public awareness. There 
has been a significant and sustained decrease in malaria 
case notifications since 2000, as a result of intensive indoor 
residual spraying including the use of DDT to combat 
insecticide-resistant Anopheles funestus; the introduction of 
artemisinin combination therapy; and the Lebombo Spatial 
Initiative, a cross-border collaboration targeting malaria in 
eastern Swaziland, southern Mozambique and northern 
KwaZulu-Natal (KZN). Rapid malaria antigen detection 
tests are widely used for diagnosis at primary health care 
level. HIV-malaria co-infected patients who are malaria 
non-immune are at risk for severe malaria. Renal failure has 
been identified as a particular complication in this group 
of patients.  Despite successes in malaria control in South 
Africa, many challenges remain.
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surveillance, epidemic preparedness and response, malaria 
advocacy, and information, education and communication.5
There has been a significant and sustained decrease in 
malaria case notifications, from 64 622 cases in 2000 to around 
8 000 in 2006, as a result of a number of initiatives, among 
which are intensive indoor residual spraying including the 
use of DDT to combat insecticide-resistant A. funestus, the 
introduction of artemisinin combination therapy (ACT) for 
treatment of uncomplicated malaria,6 and the Lebombo Spatial 
Initiative, a cross-border collaboration targeting malaria in 
eastern Swaziland, southern Mozambique and northern KZN.7,8
Vector control in South Africa 
Historically, malaria control in Africa has relied mainly on 
residual insecticide spraying of houses, capitalising on the 
feeding and resting behaviour of vectors. Its success depends 
on the assumption that the vectors bite humans indoors then 
rest on the walls. This is true of the two major vectors A. 
gambiae and A. funestus (and resulted in the elimination of 
the latter from its former range in South Africa). A. arabiensis, 
with its wider range of behaviours, can be controlled but 
not eliminated with residual spraying of houses. Residual 
spraying is labour-intensive and expensive, and requires a 
strong vertical programme to maintain efficiency. It has been 
highly successful in South Africa but has not been sustainable 
on a wide scale elsewhere in Africa. A. arabiensis breeds in 
small, sunlit temporary pools such as cattle hoofprints, and 
is not amenable to larval control, unlike A. funestus, which 
prefers more permanent water. The latter vector species, 
highly susceptible to residual house spraying for the above 
reasons, had been eliminated from the malaria transmission 
area in KZN many years previously. In 1996, bowing to 
international environmental pressure, the South African 
malaria control programme replaced DDT with synthetic 
pyrethroid insecticides. The incidence of malaria in the 
area rapidly increased five-fold to around 60 000 cases per 
year; a confounding factor was widespread resistance to 
sulphadoxine-pyrimethamine (SP –  Fansidar), which had 
been used as first-line treatment for the previous decade. 
In 1999, pyrethroid-resistant A. funestus was found resting 
indoors in sprayed houses – an invasion from neighbouring 
Mozambique.9,10 A change in first-line treatment from SP 
to artemether-lumefantrine (Coartem) and reversion to 
DDT house-spraying has brought the malaria incidence to 
normal levels.7,8 This illustrates the importance of clinical and 
laboratory monitoring of antimalarial drug resistance in the 
parasite, and the entomological monitoring of vectors and 
insecticide resistance. More recently, in 2006, the World Health 
Organization (WHO) gave its full support and advised the use 
of DDT for indoor residual spraying.
Malaria management
There are four species of plasmodia that infect humans. 
Plasmodium falciparum accounts for the majority of malaria 
cases in southern Africa and is the predominant species 
associated with severe and fatal disease. Almost all South 
Africans are non-immune, including residents of seasonal 
malaria transmission areas, and are therefore at risk for 
developing severe malaria. Early, effective case management 
is one of the cornerstones of malaria control. The sustainable 
supply and rational use of effective antimalarials is required 
both for clinical cure and for reduction in malaria transmission. 
The choice of chemotherapy for malaria is dependent on the 
severity of disease, the known or suspected resistance pattern 
of the parasite in the area where the malaria infection was 
acquired, the species of parasite, patient characteristics (age, 
pregnancy, co-morbidity, allergies, other medications) and 
the presence or absence of vomiting. It is recommended that 
patients receive prompt treatment with the most effective 
treatment regimen available. Drug choices may change over 
time depending on development of parasite resistance and 
availability of other anti-malarial treatment.6 Chloroquine (CQ) 
was the mainstay of antimalarial treatment and prevention 
for many decades after its widespread use began in the 1940s. 
Starting in 1959 in two foci – South America and Southeast 
Asia – chloroquine resistance (CQR) has gradually spread 
to most of the tropical world, sparing only parts of Central 
America, North Africa, the Middle East and East Asia. The 
most significant area affected by CQR is sub-Saharan Africa, 
which represents 90% of the world’s malaria mortality.
Parasites with low-level CQR may still show partial 
responses to CQ treatment, especially in those patients who are 
semi-immune. Chloroquine is therefore still used as it is cheap, 
but it is not reliable for treating severe malaria or malaria in 
non-immunes. By 1988, CQR was a significant problem in 
KZN, leading to treatment failures and necessitating a change 
to SP as first-line treatment for uncomplicated malaria. The 
provinces of Mpumalanga and Limpopo followed suit in 
1997 because of rising CQR.11 By 2001, SP resistance in KZN 
necessitated a further change and was replaced by artemisinin 
combination therapy (ACT) in the form of artemether-
lumefantrine. Together with the re-introduction of DDT for 
indoor residual spraying, this led to a profound reduction in 
malaria incidence, hospital admissions for malaria-related 
illness, and mortality.7 Although resistance to SP remained 
low, Mpumalanga and Limpopo provinces changed to ACT 
in 2003 and 2004 respectively, in accordance with the WHO 
recommendations for the use of combination therapy. 
The use of monotherapy for malaria throughout the world 
has resulted in the development of parasite resistance to 
sequential single-drug regimens. The concept of combination 
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therapy for malaria is based on the potential of two or 
more simultaneously administered schizontocidal drugs 
with independent modes of action to improve therapeutic 
efficacy and also to delay the development of resistance to 
the individual components of the combination. A strategy 
is to design the combination so that one drug (typically an 
artemisinin derivative such as artemether) acts extremely 
rapidly to dramatically reduce the parasite load, and the 
other is longer-acting (e.g. lumefantrine, SP) to mop up 
any surviving parasites. In such small surviving numbers 
of parasites, the probability of resistant mutants occurring 
is much lower than at the start of combination therapy.12,13 
Artemisinin-based combination therapy (ACT) is now 
generally considered as the best current treatment for 
falciparum malaria. ACTs have the advantages of rapid clinical 
and parasitological response, improved cure rates, decreased 
malaria transmission and the potential to delay antimalarial 
resistance.13 Artemether-lumefantrine is the only ACT currently 
registered in South Africa.
The artemisinins are derived from the wormwood plant, 
Artemesia annua, which has been used in China to treat fever 
for 3 000 years. The active ingredients were identified in 
1970, and a number of derivatives of this compound have 
been used successfully in the treatment of drug-resistant P. 
falciparum malaria. These include artemether, artesunate and 
dihydroartemisinin. They differ in their efficacy, absorption, 
bioavailability and toxicity.  The artemisinins are the most 
rapidly acting antimalarial drugs, and clear parasites rapidly 
from the peripheral blood and have a broad stage of action. 
They are well tolerated, have a favourable safety profile, 
and are highly effective against both uncomplicated and 
severe P. falciparum infections as well as the blood stages of P. 
vivax infections. Limited safety data preclude routine use in 
pregnancy. Artemisinins may reduce malaria transmission in 
medium-risk areas by decreasing gametocyte development, 
but this advantage has yet to be demonstrated in high 
transmission areas. When used as single-drug therapy for 
short periods, recrudescence is common, and therefore these 
drugs should always be used in combination with a longer-
acting antimalarial.13,14 Quinine remains an alternative to ACT 
for treatment in South Africa. Resistance has been slow to 
develop in South America and Southeast Asia, and high-grade 
resistance has never been well documented. Cure rates in SE 
Asia are declining, and it is now usually given in combination 
with the antibiotics doxycycline or clindamycin, which also 
have antimalarial activity.
Diagnosis of malaria
The prompt and accurate diagnosis of malaria is important 
because of its potential for rapid and serious clinical 
deterioration to complicated and possibly fatal disease states. 
Three components contribute to an optimum diagnostic 
outcome: awareness, which includes taking an adequate 
travel history and also remembering that malaria transmission 
occasionally occurs outside endemic areas (Odyssean or 
airport malaria, and needle and transfusion malaria); clinical 
astuteness and experience; and laboratory tests. Microscopy 
of blood smears stained with Romanowski stains (Giemsa or 
similar) is the traditional laboratory method and is still the 
mainstay of diagnosis. It requires skill and experience that is 
not always available, and modern technology has provided 
rapid tests, based on lateral-flow immunochromatographic 
(‘dipstick’) detection of malaria antigens, that are suitable 
for use by persons without specific laboratory training. Most 
commercially available tests detect the P. falciparum histidine-
rich protein 2 (PfHRP-2) antigen; pan-specific antigens such 
as lactate dehydrogenase or aldolase will detect other species 
as well, with variable sensitivity.12,15,18 Limited accessibility 
to laboratories for the rapid diagnosis of malaria in the rural 
areas of South Africa, particularly with a need for a definitive 
malaria diagnosis with the use of more expensive treatment 
options, led to the introduction of rapid malaria tests in rural 
clinics and health centres.16 These tests are highly sensitive and 
specific for P. falciparum, but results are highly dependent on 
the quality of the rapid test, and  appropriate storage, use and 
interpretation in the field.16 The WHO is working on systems 
to improve rapid test kit pre-accreditation evaluation and 
post-production quality testing. Molecular techniques such as 
the polymerase chain reaction (PCR) are normally not suitable 
for routine diagnosis of malaria, but are important tools for 
epidemiological and parasitological research. The advent of 
automated DNA extraction and real-time PCR may change this 
situation soon, but expense is likely to remain a constraint for 
widespread use of PCR.
Severe malaria
P. falciparum infections may progress rapidly to a fatal multi-
system disease. The key factors in preventing severe malaria 
are early and accurate diagnosis and urgent treatment with 
effective drugs. In areas of high transmission in Africa, the 
highest mortality is in infants, while adults are largely semi-
immune. In South Africa, because of much lower transmission 
intensity, all age groups are vulnerable to severe disease. 
Complications can develop rapidly within 48 hours of the onset 
of malaria disease in any non-immune person, but especially in 
young children and pregnant women. Immunocompromised 
patients and those without a functioning spleen are also at risk 
for severe malaria. The clinical manifestations of severe malaria 
depend on the age of the patient. In children, hypoglycaemia, 
convulsions, and severe anaemia are relatively common, 
while acute renal failure, jaundice, and ARDS are more 
common in adults. Cerebral malaria, shock and acidosis may 
occur at any age. Pregnant woman are particularly at risk for 
hypoglycaemia, anaemia, and ARDS, as well as fetal loss.6,17
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Currently, intravenous quinine is the only treatment 
available in South Africa for patients with severe malaria. 
However, intravenous artesunate has been shown to reduce 
mortality from severe malaria by 34.7% (15% mortality with 
IV artesunate v. 22% with IV quinine) in a large (N=1 461, 
including 202 children) randomised controlled trial, in addition 
to its other advantages of rapid action in terms of parasite 
clearance, safety and ease of administration. Thus, for every 11 
to 20 patients with severe malaria treated with IV artesunate 
instead of IV quinine, an additional life is saved.18 The WHO 
now recommends this as the treatment of choice for severe 
malaria in adults. Multi-centre randomised controlled trials are 
currently being conducted to compare intravenous quinine and 
artesunate in African children with severe malaria. 
Mortality and morbidity studies in South Africa have 
identified the following as the main causes of unfavourable 
outcome: late presentation to health facilities, particularly 
in patients in low-risk areas; those with co-morbid disease, 
especially HIV co-infection; failure to consider malaria as 
a cause of fever; and poor management of malaria-related 
complications.19,20 
Resistance builds up rapidly in malaria parasite populations 
when they are exposed to long periods of sub-therapeutic 
levels of antimalarials. Monitoring for drug resistance and 
safety is an essential component of any national drug policy 
when new drug regimens are introduced.  In South Africa, 
the South East African Combination Anti-malarial Therapy 
(SEACAT) initiative was established at sentinel sites and aims 
to monitor resistance. Clinical and parasitological response to 
treatment is monitored in a cohort of patients. With the major 
decrease in malaria cases, measuring molecular surrogates 
of resistance may act as a guide to the development of 
resistance. The major effects of antimalarial drug resistance are 
progressively increasing morbidity, mortality and transmission, 
as well as increased costs, potential toxicity and side-effects, 
and concerns about efficacy of the alternative drugs. There 
is a very limited range of available alternative agents, hence 
the growing recognition of the importance of careful selection 
of combinations of drugs that will delay the emergence of 
resistance.21
HIV and malaria
Large numbers of HIV patients live in areas where malaria 
is endemic or where there is risk of unstable malaria. The 
interaction between the two diseases is unclear. HIV-infected 
patients who develop malaria may present late to health 
centres, and the diagnosis may be missed because of symptoms 
common to the two diseases. HIV-infected individuals who 
live in malaria endemic areas and who may be malaria semi-
immune, are at increased risk of symptomatic parasitaemia 
and/or may exhibit higher levels of peripheral parasitaemia 
than semi-immune adults who are HIV-negative. HIV-malaria 
co-infected patients who are malaria non-immune are at risk 
for severe malaria. As HIV progresses and immunosuppression 
worsens, the risks of severe malaria increase. Renal failure 
has been identified as a particular complication in this group 
of patients. It is unclear how HIV infection modifies the 
therapeutic response to antimalarials. Increased parasite 
burdens and reduced host immunity, both of which occur with 
HIV infection, are associated with increased failure rates.22,23
Non-falciparum malaria, malaria in returning 
travellers, and Odyssean malaria
In sub-Saharan Africa, between 5% and 10% of malaria 
infections are caused by the other Plasmodium species, namely 
P. vivax, P. ovale and P. malariae. P. vivax is a parasite of both 
tropical and temperate climates, and accounts for the majority 
of malaria in Central America, the Middle East and Oceania. 
In West Africans, who lack the Duffy blood group, P. vivax 
malaria is absent. The core area for P. ovale is tropical Africa, 
and a separate focus is well established in Southeast Asia. Little 
is known of the extent of non-falciparum malaria in South 
Africa. Malaria in returning travellers is an increasing and 
significant problem. A recent study in this group in Gauteng 
province has shown a significant delay in presentation to 
health practitioners, a higher mortality than in the traditional 
transmission malaria areas with established malaria control 
programmes, and a definite need for health promotion to 
advise travellers on prevention of malaria (I Weber, personal 
communication). Forty-six cases of Odyssean malaria were 
identified in Gauteng province over the period 1996 - 2004. 
These most likely resulted from infection transmitted by 
mosquitoes imported in various forms of transport including 
suitcases, mini-buses and aeroplanes. Factors contributing 
to delay in diagnosis and high mortality in this group are 
the nonspecific nature of malaria, which can mimic inter alia 
septicaemia, viral hepatitis and influenza; the absence of a 
history of travel; and automated routine laboratory testing that 
is not designed to detect parasites.24
Conclusion
The ultimate goal of malaria vaccine research is an effective, 
affordable vaccine against P. falciparum. There are major 
immunological problems to overcome. The immediate 
requirement is discovering how to induce strong, non-strain-
specific, durable immune responses; to identify protective 
antigens for stage-specific immunity; and to combine 
immunogens successfully. Some recent small-scale clinical trials 
have shown progress towards reaching these goals.26 Despite 
successes in malaria control in South Africa, many challenges 
remain. Importation of malaria cases, the potential for ongoing 
antimalarial drug resistance, vector insecticide resistance, a 
large HIV epidemic, and a struggling health service, leave no 
room for complacency.
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